Work

Quality-Of-Life (Qol), Tolerability, and Supportive Care Results: Necitumumab Phase 3 Squire Study

Year: 2014

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu349.46

Authors: M. Reck, M.A. Socinski, A. Luft, A. Szczesna, M. Dediu, R. Ramlau, G. Losonczy, O. Molinier, C. Schumann, J. Brown, V. Soldatenkova, N. Chouaki, N. Thatcher

Institutions: LungenClinic Grosshansdorf, University of Pittsburgh, University of Pittsburgh Medical Center, Institutul Oncologic Bucuresti, Institutul Clinic Fundeni, Poznan University of Medical Sciences, Semmelweis University, Centre Hospitalier du Mans, Universität Ulm, University Hospital Ulm, Eli Lilly (United Kingdom), Eli Lilly (Germany), The Christie Hospital, The Christie NHS Foundation Trust

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2342934429

FWCI: 0.267

Cites:

Cited by: 1

Related to: 10